Medicare and Patient Assistance: Program Eligibility Is Not Uniform

What 'Patient Assistance' Means for a Medicare Beneficiary

For a market access, hub, or specialty pharmacy team weighing assistance options for a Medicare beneficiary facing high specialty-drug cost sharing, the first answer is short: patient assistance is not one program with one eligibility test. For someone enrolled in a Part D plan or a Medicare Advantage drug plan, cost-reducing assistance includes statutory low-income subsidies, state programs, independent charitable disease funds, and manufacturer free-drug patient assistance programs (PAPs). A separate payment-smoothing option can change when bills are paid without reducing the cost. Different administrators apply different tests before any assistance is awarded.

Manufacturer copay coupons, the default affordability tool for commercially insured patients, are generally closed to Medicare beneficiaries. Manufacturer copay terms exclude people in federal or state healthcare programs; Pfizer's, for example, state that patients who participate in programs such as Medicaid or Medicare are not eligible for co-pay assistance. The underlying reason is the federal Anti-Kickback Statute, under which OIG has said manufacturer subsidies of Part D cost sharing present heightened risks. When a commercially insured patient moves to Medicare, the card typically stops applying and the patient faces the Part D plan's own cost sharing. The defined standard benefit in 2026 has a $615 deductible, then 25% coinsurance until TrOOP reaches $2,100; actual plans can use different deductibles and tier copays.

Each of the remaining routes tests something different:

• Statutory subsidies (Extra Help/LIS and Medicare Savings Programs): The Social Security Administration (SSA) decides Extra Help applications and state Medicaid agencies run Medicare Savings Programs (MSPs). Extra Help applications test countable income and resources, with income below 150% of the federal poverty level (FPL); MSP rules and resource exclusions vary by state. Automatic Extra Help follows certain existing public-program eligibility, without a new SSA application.

• State Pharmaceutical Assistance Programs (SPAPs): State-run programs whose design varies widely, from Part D wraparound coverage to condition-specific programs such as AIDS Drug Assistance Programs (ADAPs). Eligibility is set state by state.

• Independent 501(c)(3) charitable foundations: Charities such as the HealthWell Foundation and TotalAssist (the program Patient Advocate Foundation launched in July 2026 after merging with the PAN Foundation) pay cost sharing through disease-specific funds. They require insurance that covers part of the treatment, set their own income limits, and can help only when the relevant fund is open.

• Manufacturer free-drug PAPs: These operate outside the Part D benefit, supply product rather than paying copays, apply their own income-verification rules, and add program-specific gates: $600 already paid for prescriptions in the current calendar year (GSK), an either/or test on plan access or LIS status (Sanofi), or prior enrollment in the Medicare Prescription Payment Plan (Pfizer).

• Medicare Prescription Payment Plan (MPPP): An Inflation Reduction Act payment option, available since 2025, that lets Part D enrollees pay out-of-pocket costs in monthly bills from their plan. Medicare.gov is explicit that it doesn't save you money or lower your drug costs, and it lists Extra Help, MSP, SPAP, and coupon-program users among those for whom it may not be the best choice.

The table below splits the statutory route into Extra Help and Medicare Savings Programs, giving six rows. Dollar figures are 2026 values as published on the pages checked on October 4, 2026.

Why Copay Cards Stop at the Medicare Boundary

The exclusion traces to the federal Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)), which prohibits offering or paying remuneration to induce purchases of items paid for by federal health care programs. In commercial insurance, a copay card lowers what the patient pays while the insurer pays the rest. When the payer is a Part D plan, OIG's view is that a manufacturer subsidy of the patient's cost sharing can work as an inducement to use the manufacturer's product, and that product is billed to a federal program.

In November 2005, shortly before the Part D benefit began, OIG published its Special Advisory Bulletin on Patient Assistance Programs for Medicare Part D Enrollees (70 FR 70623). The bulletin says manufacturer PAPs that subsidize Part D cost-sharing amounts "present heightened risks under the anti-kickback statute." It is guidance describing OIG's enforcement view, not a statutory ban and not a safe harbor. Manufacturer copay programs are generally written to exclude federal-program beneficiaries in line with it.

The bulletin also describes a lower-risk route. OIG said manufacturer donations to an independent, bona fide charity that subsidizes Part D cost sharing "should raise few, if any, anti-kickback statute concerns" when five conditions are met:

1. No manufacturer control: Neither the manufacturer nor any affiliate exerts direct or indirect influence or control over the charity or its subsidy program.

2. Independent awards: The charity awards assistance in a truly independent manner that severs any link between the manufacturer's funding and the beneficiary.

3. No regard to product or plan choice: Assistance is awarded without regard to the manufacturer's interests or to the beneficiary's choice of product, provider, practitioner, supplier, or Part D plan.

4. Uniform financial need: The charity bases assistance on a reasonable, verifiable, and uniform measure of financial need, applied consistently.

5. No correlating data: The manufacturer does not solicit or receive data from the charity that would let it correlate its donations with the number of subsidized prescriptions for its products.

Two further points in the bulletin matter for routing. Manufacturers should not influence how disease categories are identified, and should limit earmarked donations to programs whose categories follow widely recognized clinical standards and cover a broad spectrum of available products. And a foundation formed, funded, or controlled by a manufacturer is not a bona fide independent charity for this purpose. These are the bulletin's published conditions; subsequent OIG guidance and the facts of a particular arrangement also matter.

Statutory Programs: Extra Help, Medicare Savings Programs, and SPAPs

Before turning to manufacturer programs or charitable grants, screen for the statutory programs. They are not time-limited grants, and some private programs condition their own help on statutory status. Sanofi's Part D route, for example, requires that an applicant has no access to the product through insurance or is not eligible for or enrolled in the Low Income Subsidy, and Pfizer says patients prescribed certain medicines may first be required to seek alternate forms of assistance.

2026 Extra Help (Low-Income Subsidy / LIS) Financial Thresholds

Extra Help helps with Part D premiums, deductibles, and copayments. Its application screen is separate from automatic eligibility. Medicare.gov also states that Extra Help is unavailable in Puerto Rico and the other U.S. territories; assistance there follows different programs. For applicants in the states and DC, the 2026 published tests are:

• Income: Medicare.gov and SSA's August 2026 edition of Understanding the Extra Help With Your Medicare Prescription Drug Plan (EN-05-10508) both list $23,940 for an individual and $32,460 for a married couple living together. Those figures correspond to 150% of the 2026 poverty guideline in the 48 states and DC. Apply the program's countable-income rules rather than treating gross receipts as the eligibility result; earnings, supported family members, and Alaska or Hawaii can change the screen.

• Resources: $18,090 for an individual and $36,100 for a married couple living together. SSA's operating manual (POMS HI 03001.005) notes that the higher published resource limits include a $1,500-per-person burial-funds exclusion when the applicant expects to use resources for burial or funeral expenses. Without that exclusion the limits are $16,590 for an individual and $33,100 for a couple. SSA counts bank accounts and certificates of deposit, stocks, bonds, mutual funds, individual retirement accounts (IRAs), real estate other than the primary residence, and cash. It does not count the primary residence, vehicles, personal possessions, life insurance policies, or burial expenses.

• One level of subsidy: Effective January 1, 2024, the Inflation Reduction Act raised the full-subsidy income limit from below 135% to below 150% FPL and eliminated the partial subsidy. Everyone who qualifies now gets the full subsidy: a $0 deductible, a $0 premium for benchmark plans, and 2026 copays of no more than $5.10 for a generic and $12.65 for a brand-name drug per prescription (POMS; Medicare.gov's Medicare Savings Programs page states the same $12.65 ceiling).

Deemed Eligibility vs. SSA-1020 Application Mechanics

Medicare intake turns on whether a beneficiary is deemed eligible or has to apply:

Beneficiaries are automatically deemed eligible for Extra Help if they have full-benefit Medicaid, belong to a Medicare Savings Program (Qualified Medicare Beneficiary [QMB], Specified Low-Income Medicare Beneficiary [SLMB], or Qualifying Individual [QI]), or receive Supplemental Security Income (SSI). They do not file a separate application; as the PAN Foundation's Extra Help explainer puts it, they receive a letter about Extra Help from Medicare.

Everyone else applies to SSA on Form SSA-1020, online, by phone, or at a local office. SSA's publication says it compares the applicant's information with data available from other government agencies, and the PAN Foundation's explainer notes that applicants are not asked for proof with the application and that SSA sends a decision letter in about six weeks. That is a different evidentiary model from manufacturer PAPs, which ask for income documents up front. The Extra Help application can also start a Medicare Savings Program application: SSA sends the information to the state unless the applicant says not to.

The September 'Loss of Deemed Status' Cycle

Deemed Extra Help is not permanent. When a beneficiary no longer qualifies for Medicaid, no longer belongs to a Medicare Savings Program, or no longer gets SSI, CMS tells them that their automatic Extra Help will end on January 1 of the following year.

CMS's loss-of-deemed-status notice (CMS Product No. 11198) is printed on grey paper and is scheduled to be mailed in September together with an Extra Help application. It tells the beneficiary that they may still qualify but must apply, and that they should apply as soon as possible so there is no gap in help. If the person later regains Medicaid, MSP, or SSI status, they are automatically deemed again and CMS sends a notice on purple paper. For hub teams following Medicare patients on high-cost therapy, September through December is the window to catch these notices before January claims.

SSA may select an application-based recipient for an eligibility review; it does not send a review form to every recipient each year. Its August 2026 booklet describes annual reviews, usually at the end of August, using form SSA-1026. A selected recipient has 30 days to return it. Adjustments take effect the following January, and failure to return the form can end Extra Help the following year.

Medicare Savings Programs: Federal Floors, State Rules

Medicare Savings Programs are run by states, and the state decides which of the four programs (QMB, SLMB, QI, or QDWI) an applicant qualifies for. Medicare.gov publishes federal income and resource limits but says applicants may still qualify in their state even if their income or resources are higher, because some states do not count certain types or amounts of income or resources. QI has its own constraints: enrollees must reapply every year, and states approve applications first come, first served, with priority for people who had QI the previous year. Because QMB, SLMB, and QI enrollment confers Extra Help automatically, approval for one of those programs also settles the Part D subsidy question.

State Pharmaceutical Assistance Programs (SPAPs)

Many states also run State Pharmaceutical Assistance Programs. SPAPs are recognized in Section 1860D-23 of the Social Security Act and can provide wraparound help alongside Part D, but their design, covered populations, and eligibility rules are set state by state.

A state-program count is not a useful eligibility screen: general wraparound assistance, condition-specific ADAPs, and discount programs serve different populations. Use the state-assistance lookup linked from Medicare.gov's Help with drug costs page and then read the state program's own residency, income, diagnosis and Part D coordination rules. A discount program is not automatically a qualified SPAP. Qualified SPAP payments can count toward TrOOP; CMS also describes data exchanges with SPAPs, ADAPs, and PAPs to coordinate benefits and keep claims and TrOOP records accurate.

Manufacturer PAPs: Three Programs, Three Different Medicare Gates

When a beneficiary is over the statutory limits and no charitable fund is open, manufacturer PAPs are the next route. OIG's 2005 bulletin describes free-drug PAPs that operate entirely outside the Part D benefit as posing reduced risk when they follow safeguards such as notifying the plan so that no claim is paid and the drug does not count toward TrOOP, and providing assistance for the full coverage year. Because each manufacturer writes its own Medicare terms, the gates differ from program to program.

Three programs' Medicare pages, read on October 4, 2026, show how far they diverge:

1. GSK: The $600 Calendar-Year Spend Gate

The GSK Patient Assistance Program has a separate Medicare Part D track. Its Medicare page lists these conditions:

• Residency and plan: Live in the United States or Puerto Rico and have a Medicare prescription drug plan. Puerto Rico residents must also not be eligible for the Government Health Plan Mi Salud, or must have applied and been denied.

• Prior spend: Have paid a total of $600 for prescriptions in the current calendar year.

• Income: Household income within the program's table: $47,880 for one person and $64,920 for two in the 48 contiguous states and DC, with separate tables for Alaska, Hawaii, and Puerto Rico. The 48-state figures equal 300% of the 2026 poverty guideline.

The spend test is a timing gate. An applicant who has not yet paid $600 for prescriptions this calendar year does not meet it, and the count starts again each January. GSK's Medicare page does not list the required documents or how long an approval lasts, so confirm both from the current application before submitting.

2. Sanofi Patient Connection: The Plan-Access-or-LIS Test

Sanofi Patient Connection sets different conditions for Part D and Part B enrollees:

• Part D: Applicants must have no access to the prescribed product through their insurance or not be eligible for or enrolled in the Low Income Subsidy (LIS). Read the "or" carefully: an LIS enrollee whose plan does not cover the product can meet the first condition, while an applicant whose plan does cover it must show they are not LIS-eligible. For an LIS-eligible applicant whose plan covers the drug, the practical first step is Extra Help.

• Part B: Applicants must have no access to the prescribed product or treatment through their insurance or supplemental insurance coverage.

• Income: Annual household income at or below 400% of the current federal poverty level.

• Scope: Not all Sanofi products are covered, so check the program's medication list and application before applying. The Medicare page does not list required documents or the enrollment term.

3. Pfizer RxPathways: The Payment-Plan and Current Income Screens

The Pfizer RxPathways Patient Assistance Program serves uninsured patients and patients with government insurance, including Medicare, and excludes commercially insured patients. Its Medicare conditions are the most procedural of the three:

• Payment-plan prerequisite: For applicable products covered and reimbursed by Medicare Part D or an MA-PD plan, Pfizer's current eligibility section requires MPPP enrollment, a check that the annual out-of-pocket cap has not been met, and prior authorization if the insurer requires it. The payment plan remains a voluntary Medicare election; Pfizer makes it a condition of its PAP route for those products.

• Current income screen: The current eligibility section says annual household pre-tax income cannot exceed 300% FPL. The same page retains FAQ language about 500% or 600% product tiers and a separate block using 2021 guidelines. Those older blocks do not establish a higher 2026 ceiling. Use the current requirements and confirm the prescribed product's active enrollment instructions.

• Other eligibility checks: The product must be available through the PAP, the prescription must be for an FDA-approved diagnosis, and the applicant must meet the residency, outpatient-prescriber and inability-to-afford requirements. Medicare enrollment and income alone do not approve the application.

• Enrollment term: The FAQ describes 12 months for uninsured patients and enrollment through calendar-year end for insured patients, but it sits alongside stale insurance and income language. Confirm the term and renewal instructions on the current product application and award; do not assume the FAQ establishes today's term.

• Income proof and caveats: Proof of income such as a W-2, a paycheck stub, or the prior year's tax return. Pfizer notes that patients prescribed certain medicines may first be required to seek alternate forms of assistance and that eligibility rules are subject to change at any time. For matching income documents to each program, see our guide on patient assistance program income documentation.

The table summarizes what each program's own Medicare page said on October 4, 2026. Where a page is silent, the table says so rather than filling the gap.

Charitable Foundations: Fund Status Decides as Much as Income

Manufacturer PAPs supply product outside insurance. Independent 501(c)(3) foundations work the other way: they pay the patient's cost sharing (deductibles, copayments, and coinsurance) under the patient's own Part D or Part B coverage. Their gates are not only about income.

Three Rules Charities Apply

HealthWell Foundation's published eligibility rules illustrate the pattern:

• Insurance that covers part of the treatment: Applicants must have some form of health insurance (private insurance, Medicare, Medicaid, TRICARE) that covers part of the cost of treatment. Drug discount cards do not qualify as insurance, and patients without prescription insurance are referred elsewhere, such as to manufacturer PAPs.

• Charity-set income limits: HealthWell assists people with incomes up to 400–500% of FPL and also considers household size and the cost of living where the patient lives. These limits are set by each charity, not by a federal rule, and differ across charities and funds.

• An open fund for the diagnosis and drug: The applicant must receive treatment in the United States, the diagnosis must be in a currently open fund, and the medication must be covered under it. HealthWell requires diagnosis verification signed by a physician, nurse practitioner, or physician assistant. HealthWell says it frequently opens and reopens programs as funding becomes available. A closed fund cannot be worked around by income or insurance status, so record the fund name, status, and date checked, and recheck.

The 2026 Foundation Landscape: PAN/PAF Merger and TotalAssist

In March 2026, Patient Advocate Foundation and the PAN Foundation announced a strategic merger; the combined organization operates as Patient Advocate Foundation. On July 1, 2026, it launched TotalAssist, a single financial-assistance program for both legacy organizations.

For access and hub navigators, the merger has two operating implications:

• Legacy grants run their course: Patients holding legacy PAN Foundation or Patient Advocate Foundation grants keep access to their assistance as originally awarded for their entire 12-month eligibility period.

• Renewals move to TotalAssist: All new enrollments and renewals from either legacy program now run through TotalAssist, so a legacy grant's renewal date is when the case moves to the new program. The organization's integration timeline runs through 2027 and program information still sits partly on legacy websites, so confirm fund status and contacts through TotalAssist rather than old pages. For the financial scale of the largest copay charities, see our IRS Form 990 analysis of pharma copay foundations.

The TrOOP Line and the 2026 Part D Redesign Backdrop

Whether a payment counts toward true out-of-pocket costs (TrOOP) decides how assistance interacts with the benefit. The Inflation Reduction Act redesign began in 2025; for 2026, CMS's Part D redesign program instructions set these parameters:

• The $2,100 threshold and $615 deductible: The 2026 annual out-of-pocket threshold is $2,100 (the 2025 cap of $2,000, indexed) and the deductible is $615. In the defined standard benefit, enrollees pay 25% coinsurance after the deductible until TrOOP reaches the threshold; actual plan tiers and deductible design can differ. In the catastrophic phase they pay no cost sharing for covered Part D drugs.

• What counts: Beneficiary payments and qualifying assistance toward covered Part D cost sharing can advance TrOOP. Examples include independent-charity payments, qualified SPAP payments and Extra Help subsidies. The program type and coordination rules matter: this is not a claim that every third-party payment qualifies. Confirm the actual accumulator with the Part D plan, especially when another program is paying.

• What does not count: CMS states that a PAP's assistance on behalf of a PAP enrollee does not count toward TrOOP, because PAPs serve Part D enrollees by operating "outside the Part D benefit." PAPs that want data-file exchanges with CMS to learn which of their enrollees are in Part D plans must first submit a PAP attestation. Medicare.gov adds that discount cards are not creditable coverage and do not count toward the deductible or the out-of-pocket maximum.

The Medicare Prescription Payment Plan: Smoothing vs. Assistance

The Medicare Prescription Payment Plan, available since 2025, replaces pharmacy-counter payment for covered Part D cost sharing with monthly plan bills. Bills reflect incurred costs, any unpaid balance and the months remaining in the year, and can change as prescriptions are filled. Reaching the TrOOP cap does not erase an outstanding payment-plan balance. The cap covers Part D drug cost sharing; it does not cap premiums, Part B costs or purchases outside the Part D benefit.

Medicare.gov's guidance on the payment option explains that payment smoothing changes the timing of bills without reducing the total. It may be less useful for people receiving or eligible for Extra Help or an MSP, people receiving other drug-cost assistance, or people joining late in the year. An enrollment prerequisite on a manufacturer PAP is a separate program rule, rather than evidence that the payment plan lowers costs.

For someone with Extra Help, each 2026 prescription costs no more than $5.10 for a generic or $12.65 for a brand-name drug, so spreading payments adds a monthly bill without changing the total. That tension matters for Pfizer's Medicare route, which requires payment-plan enrollment first: for an LIS-eligible patient, the statutory subsidy is usually the better first stop. For payment-plan onboarding problems, see our analysis of Medicare Prescription Payment Plan opt-in failures and our evaluation of the $2,100 out-of-pocket cap's impact on hub operations.

A Dated Eligibility Routing Workflow with a Worked Record

For Part D and MA-PD cases, a useful screening sequence is existing public-program status, potential statutory or state assistance, current disease-fund options, then the prescribed product's manufacturer PAP. Run checks in parallel when a case needs it; this sequence is not a universal requirement to exhaust every program. Keep the dated source and the documents each administrator actually requests. The diagram is a screening aid; an application remains subject to the program's decision.

flowchart TD
    A["Confirm Part D or MA-PD coverage and prescribed product"] --> B["Manufacturer commercial copay route generally excluded"]
    B --> C{"Existing automatic Extra Help or active LIS award?"}
    C -- "Yes" --> D["Confirm status and costs with plan; deemed recipients do not file SSA-1020"]
    C -- "No or uncertain" --> E["Screen countable income and resources, household and geography; apply to SSA if potentially eligible"]
    D --> F["Check state MSP and SPAP rules separately; record current status"]
    E --> F
    F --> G["Charity screen: covered diagnosis and drug, insurance, income and treatment location"]
    G --> H{"Relevant fund open and criteria met?"}
    H -- "Yes" --> I["Request grant; record decision, term and any remaining gap"]
    H -- "No or remaining gap" --> J["Find the prescribed product's current manufacturer PAP"]
    I -- "Remaining gap" --> J
    J --> K{"Product, income, insurance, residency and other general criteria met?"}
    K -- "No or uncertain" --> R["Confirm with administrator; review other eligible assistance or voluntary payment smoothing"]
    K -- "Yes" --> L{"Read the program-specific Medicare gate"}
    L -- "GSK" --> M{"600 dollars paid for prescriptions this calendar year?"}
    L -- "Sanofi Part D" --> N{"No plan access to product, or not LIS-eligible or enrolled?"}
    L -- "Pfizer applicable covered product" --> O{"MPPP enrolled, cap not met, required PA and alternate-funding review complete?"}
    M -- "Yes" --> P["Submit current application and required records; await program decision"]
    N -- "Yes" --> P
    O -- "Yes" --> P
    M -- "No" --> R
    N -- "No" --> R
    O -- "No or uncertain" --> R
    P --> Q["If awarded: confirm supply and renewal; outside-Part-D free product adds no TrOOP"]

An intake record should keep eligibility, application completeness and an award as separate statuses. For Extra Help, note whether eligibility is automatic or application-based; for state aid, name the state and program. For a charity, record the fund, covered diagnosis and drug, open/closed status, requested verification and check date. For a PAP, record the prescribed product, accepted insurance, income definition, Medicare-specific gate, current form and any prerequisite evidence. A successful screen is a reason to continue review, not a funded grant or an approved supply. If all available routes are closed, document that result and review the covered Part D benefit and voluntary payment option without promising a replacement assistance program.

Worked Record: An Illustrative Composite

Profile (composite): Eleanor, 71, has Original Medicare (Parts A and B) and a standalone Part D plan. In January 2026 she is prescribed an oral specialty oncology drug with an assumed plan-negotiated price of $14,200 per 30-day supply. Her plan covers it with standard-benefit cost sharing, and she has no other Part D costs yet this year.

Finances (composite): Her annual income from Social Security and a pension is $32,400, about 203% of the 2026 one-person poverty guideline of $15,960 (the base implied by Medicare.gov's 150% figure of $23,940). Her countable resources are a $4,200 checking account and a $22,000 certificate of deposit, $26,200 in total.

Exposure without assistance (2026 standard benefit, first fill in January): She pays the $615 deductible, then 25% of the remaining $13,585, which is $3,396.25. Together that is $4,011.25, more than the $2,100 threshold, so her cost sharing on the first fill stops at $2,100 and later covered fills in 2026 cost $0. If she joins the payment plan in January, that $2,100 becomes 12 monthly bills of $175. Her annual exposure is the cap; the open question is whether any route can cover it.

Step-by-step screening:

1. Payer check: The coordinator confirms active Part D enrollment. The drug's commercial copay card is excluded by its own terms for a Medicare beneficiary, so it is not used.

2. Extra Help and MSP: Her income of $32,400 is above the 2026 Extra Help limit of $23,940, and her $26,200 in countable resources is above the $18,090 limit, so she screens above both limits under the stated assumptions. This composite assumes no additional income or resource exclusions and no automatic Extra Help status; it is not an SSA determination. For the MSPs, the coordinator checks her own state's limits rather than the federal floor because some states are more generous; in this composite, she is over her state's limits too.

3. Charitable funds: The navigator checks TotalAssist and HealthWell for a fund covering her diagnosis and drug. Her income, at about 203% FPL, is within HealthWell's published range (up to 400–500% FPL), and the TotalAssist fund's own limit is checked the same way, but in this composite both relevant funds are closed on the day of screening. The navigator records the fund names, status, and date, and sets a recheck.

4. Manufacturer PAP (composite assumption: a Pfizer specialty oncology product): The navigator works through Pfizer RxPathways' published Medicare conditions:

   • Income: About 203% FPL is below Pfizer's current 300% ceiling. The navigator still verifies that the assumed product accepts new PAP applications and checks its current instructions.

   • Timing: No Part D fill yet in 2026, so her annual out-of-pocket maximum has not been met. A first covered fill at the assumed price would reach the cap, changing this financial screen for the remaining year. This is a timing observation, not a reason to delay treatment or postpone a covered fill while seeking assistance; the care team and plan address timely access.

   • Payment plan: She opts in to the Medicare Prescription Payment Plan through her Part D plan, and the confirmation goes into the file.

   • Documents: Proof of income in a form Pfizer lists (in this composite, the prior year's tax return), the payment-plan confirmation, the prescription and signed application, any prior authorization her plan requires, and the applicable alternate-funding checks or denial records the program requests. Closed-fund status is recorded; it is not invented as a denial letter.

5. Disposition depends on the program: If the program approves the application, the written award establishes its term and renewal requirements. Free product supplied outside Part D adds no TrOOP. The navigator records the actual end date rather than borrowing it from stale FAQ text. If the application is denied or decided after a Part D fill, her 2026 exposure remains the $2,100 cap, which the payment plan can spread over the remaining months, and the open-fund recheck continues.

What Access and Hub Teams Should Monitor (2026–2027)

Medicare assistance rules move on several calendars at once. Six watchpoints for the 2026–2027 cycle:

• Poverty-guideline updates: HHS updates the federal poverty guidelines each year, usually in January. Extra Help limits follow them, while charities and manufacturers update their own tables on their own schedules; check the edition date rather than assuming every saved booklet is current. SSA's August 2026 booklet and Medicare.gov currently agree on the income figures.

• 2027 parameters are already posted: Medicare.gov's Extra Help page now lists 2027 terms: a $0 plan premium and deductible, copays of up to $5.80 for each generic and $14.40 for each brand-name drug, and $0 cost sharing once total costs reach $2,400. Update screening scripts and worked examples before January.

• August reviews and September notices: SSA's SSA-1026 eligibility reviews usually go out at the end of August, and CMS's grey loss-of-deemed-status notices are scheduled for September. Both feed January coverage changes.

• TotalAssist integration: Patient Advocate Foundation's integration timeline runs through 2027. Watch for fund openings and closures, renewals of legacy grants, and moved program pages.

• Manufacturer term changes: Manufacturer PAP rules can change without rulemaking; Pfizer states that its eligibility rules are subject to change at any time. The GSK spend gate, Sanofi's plan-access-or-LIS test, and Pfizer's payment-plan prerequisite are point-in-time terms as of October 4, 2026. Re-read each program's own page before every application cycle.

• OIG activity: New OIG advisory opinions or enforcement actions involving charitable assistance programs could change how disease funds are defined or operated.

Limits of this analysis: Public program pages were checked on October 4, 2026. State SPAP and MSP rules were not audited state by state. No payer claims data, approval rates or search-demand figures were used. The worked record is a composite; real cases require the administrator's eligibility decision, current plan benefits, and the product's active application instructions.

Sources

• Medicare.gov: Help with drug costs. 2026 Extra Help income and resource limits, 2027 Extra Help terms including the $2,400 threshold, automatic eligibility, state and manufacturer assistance lookups, and discount-card treatment. Accessed October 4, 2026.

• Social Security Administration: Understanding the Extra Help With Your Medicare Prescription Drug Plan (Publication EN-05-10508, August 2026). Form SSA-1020, resource and income rules, data matching, MSP referral, and SSA-1026 reviews. Accessed October 4, 2026.

• Social Security Administration: POMS HI 03001.005, Medicare Part D Extra Help (Low-Income Subsidy or LIS). 150% FPL threshold, 2026 resource limits, elimination of the partial subsidy, deemed groups, and 2026 copayments. Accessed October 4, 2026.

• Medicare.gov: Medicare Savings Programs. QMB, SLMB, QI, and QDWI; state administration and state flexibility on limits; $12.65 Extra Help ceiling for 2026. Accessed October 4, 2026.

• HHS Office of Inspector General: Special Advisory Bulletin on Patient Assistance Programs for Medicare Part D Enrollees (70 FR 70623, November 22, 2005). Anti-kickback analysis, the five conditions for independent charities, disease-category guidance, PAPs outside the Part D benefit, and TrOOP. Accessed October 4, 2026.

• CMS: Pharmaceutical Manufacturer Patient Assistance Program Information. PAPs operating outside the Part D benefit, TrOOP exclusion, and PAP attestation. Accessed October 4, 2026.

• CMS: Prescription Drug Assistance Programs (Coordination of Benefits & Recovery). Data exchanges with SPAPs, ADAPs, and PAPs and data sharing agreements. Accessed October 4, 2026.

• CMS: Final CY 2026 Part D Redesign Program Instructions (fact sheet). $2,100 out-of-pocket threshold, $615 deductible, and benefit phases. Accessed October 4, 2026.

• Medicare.gov: Medicare Prescription Payment Plan, Before using this payment option. How monthly bills are calculated and who may not benefit. Accessed October 4, 2026.

• CMS: Introduction to the Loss of Deemed Low Income Subsidy (Extra Help) Status Notice (CMS Product No. 11198). September grey-paper notice and reapplication guidance. Accessed October 4, 2026.

• GSK: Patient Assistance Program for Prescription Medicines, If You Have Medicare Part D. Current calendar-year $600 spend requirement and income tables. Accessed October 4, 2026.

• Sanofi Patient Connection: Medicare Patient Assistance Eligibility. Part D and Part B conditions, the plan-access-or-LIS test, and the 400% FPL limit. Accessed October 4, 2026.

• Pfizer RxPathways: For Patients. Insurance types served, payment-plan prerequisite, current 300% income screen, stale FAQ caveats, and proof of income. Accessed October 4, 2026.

• HealthWell Foundation: Eligibility. Insurance, income (up to 400–500% FPL), and open-fund requirements. Accessed October 4, 2026.

• Patient Advocate Foundation: About our strategic merger. March 2026 merger, July 2026 TotalAssist launch, and legacy-grant continuity. Accessed October 4, 2026.

• PAN Foundation (now Patient Advocate Foundation): Extra Help program for people on Medicare. Automatic Extra Help groups, application process, and decision timing. Accessed October 4, 2026.

• National Conference of State Legislatures: State Pharmaceutical Assistance Programs. State program types and state-by-state listings. Accessed October 4, 2026.